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Background: Infectious diseases are the leading cause of humanmorbidity andmortalityworldwide. One dramat-
ic issue is the emergence ofmicrobial resistance to antibiotics which is amajor public health concern. Surprising-
ly however, such in vivo adaptive ability has not been reported yet for many intracellular human bacterial
pathogens such as Legionella pneumophila.
Methods:We examined 82 unrelated patients with Legionnaire's disease fromwhich 139 respiratory specimens
were sampled during hospitalization and antibiotic therapy. We both developed a real time PCR assay and used
deep-sequencing approaches to detect antibiotic resistance mutations in L. pneumophila and follow their selec-
tion and fate in these samples.
Findings:We identiﬁed the in vivo selection of ﬂuoroquinolone resistance mutations in L. pneumophila in two in-
fected patients treated with these antibiotics. By investigating the mutational dynamics in patients, we showed
that antibiotic resistance occurred during hospitalization most likely after ﬂuoroquinolone treatment.
Interpretation: In vivo selection of antibiotic resistances in L. pneumophilamay be associated with treatment fail-
ures and poor prognosis. This hidden resistance must be carefully considered in the therapeutic management of
legionellosis patients and in the control of the gradual loss of effectiveness of antibiotics.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acquired resistance to antibiotics in human bacterial pathogens has
been extensively described and is associated with a high public health
and economic burden (Martínez, 2008; Skippington and Ragan, 2011;
Pendleton et al., 2013). In striking contrast, resistant mutants have
been rarely, if ever, detected in humans for many bacterial species with
strict or facultative intracellular lifestyles, including Rickettsia spp.
(agent of rickettsioses), Coxiella burnetii (Q fever), Ehrlichia and
Anaplasma species (ehrlichiosis and anaplasmosis), Chlamydia psittaci
(psittacosis), Legionella pneumophila (legionellosis), Francisella tularensises, CHU Grenoble, Institut de
e.
).
. This is an open access article under(tularemia), and Brucella melitensis (brucellosis). However, mutants
have been easily selected for when these pathogens were grown
in vitro (Rolain and Raoult, 2005; Rouli et al., 2012; Maurin et al.,
2001; Binet and Maurelli, 2005; Almahmoud et al., 2009; Sutera et al.,
2014; Ravanel et al., 2009). These occasional human pathogens thrive
in environmental or animal reservoirs, or both, and are not carried by,
nor transmitted, among humans.
L. pneumophila is a Gram-negative facultative intracellular bacterium
that multiplies in aquatic environments, especially in free-living proto-
zoa and bioﬁlms (Newton et al., 2010; Carratalà and Garcia-Vidal,
2010). Legionellosis is an acute pneumonia caused by inhalation of
aerosols containing Legionella sp., with L. pneumophila serogroup (sg)
1 accounting for more than 90% of human infections (Newton et al.,
2010; Carratalà and Garcia-Vidal, 2010). The macrolides (especially
azithromycin) and the ﬂuoroquinolones are ﬁrst-line antibiotics forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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et al., 2010; Yu et al., 2009; Pedro-Botet and Yu, 2009; Burdet et al.,
2014). However, treatment failures and relapses may occur despite ad-
ministration of an appropriate antibiotic therapy (Chidiac et al., 2012;
Jespersen et al., 2010; Yu et al., 2009; Pedro-Botet and Yu, 2009; Burdet
et al., 2014). The mortality rate of legionellosis is 10% on average, but
can be as high as 30% in immunocompromised patients (Chidiac et al.,
2012; Jespersen et al., 2010; Yu et al., 2009). Acquired resistance to
themacrolides and ﬂuoroquinolones in L. pneumophila has been readily
selected for in vitro (Almahmoud et al., 2009; Jonas et al., 2003; Nielsen
et al., 2000). In striking contrast, no macrolide resistance (Jespersen
et al., 2010; Yu et al., 2009; Pedro-Botet and Yu, 2009; Burdet et al.,
2014), and only a single case of ﬂuoroquinolone resistance has been re-
ported in clinical strains (Bruin et al., 2014). In the latter case however,
only one patientwas studiedwith onlymicrobiological approaches and,
importantly the dynamics of ﬂuoroquinolone-resistance during
infection and hospitalization was not investigated. Here, we identiﬁed
and further characterized, using molecular and genomic approaches,
the in vivo selection of ﬂuoroquinolone-resistance mutations in
L. pneumophila during a large survey of 82 unrelated legionellosis cases.
2. Methods
2.1. Patients and Clinical Samples
We studied a cohort of 82 unrelated legionellosis patients including
64 males and 18 females (mean age: 55 years, age range: 27–97 years)
that were admitted to the Grenoble University Hospital between 2006
and 2011. For diagnostic purposes, 139 lower respiratory tract samples
were collected from these patients during hospitalization. After homog-
enization of the samples (appendix p 3), routine bacteriological tests
(bacterial cultures, Legionella detection by culture and PCR) were per-
formed. The homogenized samples were then frozen at−80 °C. Based
on the criteria from the European Centre for Disease Prevention and
Control (ECDC, 2012), legionellosis diagnosis was based on the combi-
nation of clinical and radiologic ﬁndings of pneumonia, and a positive
urinary antigen test for L. pneumophila sg1 (Binax Now Legionella,
Binax, Portland, ME, USA). In addition, we tried to further conﬁrm diag-
nosis by isolation of a L. pneumophila strain from respiratory samples
and detection of L. pneumophilaDNA in the same samples using a previ-
ously described quantitative real-time PCR assay (qPCRmip assay)
(Maurin et al., 2010).
2.2. Bacterial Strains and Media
We used four reference strains of L. pneumophila sg1 (Paris, Philadel-
phia, Lens, and Lorraine) (appendix p 5), and 27 strains belonging to 18
Legionella species other than L. pneumophila (appendix p 6), that are all
ﬂuoroquinolone-susceptible. We used three ﬂuoroquinolone-resistant
mutant strains (LPPI1, LPPI4, and LPPI5) that we previously selected
in vitro from the Paris strain (appendix p 5) (Almahmoud et al., 2009).
All three have mutations in the gyrA Quinolone Resistance Determinant
Region (QRDR). For speciﬁcity purposes,weused33non-Legionellabacte-
rial strains thatwere previously isolated fromhuman respiratory samples
(appendix p 7). Legionella strains were grown on buffered charcoal yeast
extract agar plates (BCYE, Oxoid, Basingstoke, UK) at 37 °C for 48–72 h.
The other bacteria were grown on Columbia or chocolate blood agar sup-
plemented with 5% Polyvitex (bioMérieux, Marcy L'Etoile, France).
2.3. Antibiotic Susceptibility Testing
Ciproﬂoxacin MICs were determined using the E-test method
(bioMérieux). A bacterial inoculum of 1 McFarland turbidity standard
was prepared in brain–heart infusion (BHI) broth (bioMérieux), and
plated on BCYE plates carrying an E-test strip. Plates were incubated
for 3–5 days at 35 °C in a 5%-CO2 atmosphere. The MIC is given on thestrip at the inhibitory zone edge intersection (Rhomberg and Jones,
1994). We tested the 15 clinical strains of L. pneumophila sg1 sampled
from the ﬁrst respiratory samples of 15 patients (see Results section).
The L. pneumophila Paris, Philadelphia, Lens, and Lorraine strains served
as ciproﬂoxacin-susceptible controls, and the LPPI1, LPPI4, and LPPI5
strains as ciproﬂoxacin-resistant controls.
2.4. Quantitative Real-time PCR Assay Targeting the gyrA QRDR Mutations
(qPCRgyrALp)
In gram-negative bacteria, ﬂuoroquinolone resistance is most often
related to mutations occurring in the quinolone resistance determining
region of gyrA, the gene encoding the sub-unit A of DNA gyrase, espe-
cially at the hot-spot codon positions gyrA83 and gyrA87 (Escherichia
coli numbering system) (Davies and Davies, 2010; Komp Lindgren
et al., 2003; Jacoby, 2005). We previously demonstrated that gyrA83
mutations could occur in vitro in L. pneumophila, and was associated
with increased resistance to ﬂuoroquinolones (Almahmoud et al.,
2009). Thus, we developed a real-time PCR assay (qPCRgyrALp)
targeting mutations in the gyrA QRDR, especially at codon positions
gyrA83 and gyrA87.
PCR and real-time PCR experiments were performed with genomic
DNA from the relevant strains or from lower respiratory tract samples,
after DNA extraction using the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer's recommendations (appen-
dix p 3). We ﬁrst PCR-ampliﬁed and sequenced a 383-bp region of the
gyrA QRDR of 31 Legionella strains (appendix pp 3 and 6), as previously
described (Almahmoud et al., 2009). We analyzed these sequences to
design L. pneumophila-speciﬁc primers and probes to elaborate the
qPCRgyrALp assay. The sensitivity and speciﬁcity of the qPCRgyrALp
assay were ﬁrst checked using a set of 67 strains, including 7
ﬂuoroquinolone-susceptible or -resistant L. pneumophila control strains
(appendix p 5), 27 strains belonging to other Legionella species
(appendix p 6), and 33 strains belonging to other genera (appendix p 7).
2.5. Next-generation Deep-sequencing of the Legionella gyrA QRDR
Weused high-throughput pyrosequencing (appendix p 4, table 1) to
conﬁrm and quantify the presence of gyrA QRDR mutated alleles in 11
human respiratory samples, including eight qPCRgyrALp-positive sam-
ples from four patients (called patients #1 to #4), and three
qPCRgyrALp-negative samples from three patients selected randomly
(called control patients).
2.6. Patient and Other Consents
We used respiratory samples and bacterial strains collected in the
context of routine care of patients hospitalized at Grenoble University
Hospital for severe legionellosis. We have declared this collection of
human samples to the French Ministry of Education and Research
(DC-2008-677), and we have the authorization to use it for research
purposes from our ethics committee (CPP Sud-Est V). In accordance
with the French law, patients' information for this type of research is
done through a hospital medical booklet and only a non-opposition of
the patients is needed.
2.7. Role of the Funding Source
The study was sponsored by the French Centre National de la
Recherche Scientiﬁque (CNRS), Université Grenoble Alpes (UGA); and
by the Direction de la Recherche Clinique et de l'Innovation (DRCI)
Centre Hospitalier Universitaire de Grenoble.
The funding sources had no role in the study design; in data collec-
tion, analysis and interpretation; in writing of the manuscript or in the
decision to submit it for publication. We did not receive any funds to
write this article from a pharmaceutical company or other agencies.
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A positive urinary antigen test for L. pneumophila sg1 (Binax Now
Legionella, Binax, Portland, ME, USA) was found for all 82 investigated
pneumonic patients. Legionellosis diagnosis was further conﬁrmed in
15 of the 82 patients by isolation of a L. pneumophila strain from the
ﬁrst collected respiratory sample. These 15 clinical strains of
L. pneumophila displayed ciproﬂoxacin MICs ranging from 0.25 to
0.38 mg/L, whereas MICs were 0.38 mg/L for the susceptible
L. pneumophila reference strains (Paris, Philadelphia, Lens, and Lor-
raine), 1.5 mg/L for the LPPI1 mutant with a single gyrAmutation, and
2 mg/L for the LPPI4 and LPPI5 mutants with two gyrAmutations (ap-
pendix p 5). We found no mutation in the gyrA QRDR of the 15 clinical
strains. Legionellosis was also conﬁrmed in 61 (74.4%) of the 82
legionellosis patients (including 13 patients with a positive
L. pneumophila culture), by direct detection of L. pneumophilaDNA in re-
spiratory samples (112 of the 139 collected samples, 80.6%), using the
qPCRmip assay (Maurin et al., 2010). The L. pneumophila DNA load in
these samples varied from 5.8 × 102 to 6.8 × 107 genome units (GU)/
mL of sample. For 19 patients, L. pneumophila culture and PCR assays
were negative.
After standardization of the qPCRgyrALp assay, a strong ampliﬁcation
signal of the gyrAQRDRwas detected for all tested L. pneumophila strains.
Furthermore, this assay could distinguish Legionella versus non-Legionella
strains, L. pneumophila versus other Legionella species, ﬂuoroquinolone-
susceptible versus resistant mutants of L. pneumophila, and single versus
double mutants (Fig. 1; appendix p 3; appendix p 5). When applied to
the 139 respiratory samples collected from the 82 legionellosis patients,
an ampliﬁcation signal corresponding to the gyrA QRDR was detected in
114 samples (82%) from62 patients (75.6%), including 63 and 11 samples
collected from patients under and without ﬂuoroquinolone therapy, re-
spectively (Table 1). The qPCRgyrALp assay was positive for 108 (96.4%)
of the 112 samples showing a positive qPCRmip assay, but only for 7 of
the other 27 qPCRmip-negative samples (25.9%, p b 0.01), suggesting
that the DNA load in clinical samples was critical for detection of either
the mip or gyrA gene. All qPCRgyrALp-positive respiratory samples
(104) collected from 58 patients gave identical results, their melting
curve proﬁles suggesting a reference gyrAQRDR sequence (meanmelting
peak ± SD, 59.34 ± 0.41 °C) when compared to control strains (Fig. 1,
Table 1). For 4 patients however (#1 to #4), we detected melting peaks
of 56.35 ± 0.42 °C (three replicates per patient) for 6 of 11 respiratory
samples, suggesting the presence of gyrA QRDR mutations.
To conﬁrm the presence of gyrA83 or gyrA87 mutations in
qPCRgyrALp-positive samples, we tried to PCR-amplify and sequence a
383-bp fragment of the L. pneumophila gyrA QRDR directly from eight
respiratory samples of patients #1 to #4 (Table 1). Using next-Fig. 1. Detection of gyrA QRDR mutations using the qPCRgyrALp assay. Melting curves and p
(Martínez, 2008), respiratory samples from patients #1 to #4 (Skippington and Ragan, 2011), t
strain (Rolain and Raoult, 2005), the L. pneumophila Lens strain (Rouli et al., 2012), and the L. pne
(Binet andMaurelli, 2005) gyrAmutations, respectively (appendix p 5). The units of the y axes a
and 56.35 ± 0.42 °C are diagnostic of reference and mutant alleles of the gyrA QRDR, respectivgeneration deep sequencing (NGS) technology, we also determined
the frequency of these gyrA QRDR mutations by testing the same respi-
ratory samples from patients #1 to #4 and the qPCRgyrALp-negative
samples from three control patients (Table 1). We detected no PCR
product for samples from patient # 1 collected one and three days (D1
and D3) after the day of legionellosis diagnosis (D0), which may be re-
lated to low L. pneumophila DNA load (b103 GU/mL sample, as deter-
mined by the qPCRmip assay). For patient #3, a PCR product was
obtained from the D0 sample, in which we identiﬁed ﬁve mutations
none of which affected the gyrA codons 83 or 87. Two silent mutations
C219G and C264T (codons 73 and 88, respectively) occurred in the
gyrA QRDR but outside the location of the sensor probe of the
qPCRgyrALp assay, and thus had no inﬂuence on the melting peak.
The three others (T278C, A281G, and T285C at codons 93, 94, and 95, re-
spectively) were localized in the region complementary to the anchor
probe thereby explaining the observed melting peak decrease. Using
the NGS method, we conﬁrmed the lack of gyrAmutation at codons 83
and 87 for sample D0 of patient #3, and the ﬁve changes at codons 73
(C219 G), 88 (C264T), 93 (T278C), 94 (A281G), and 95 (T285C), at a fre-
quency of 85.7% of 17,060 reads. More importantly, we detected low
levels (0.023% to 0.19% of a total of 3267 to 14,716 reads) of C248T
gyrA83mutations (T83I GyrA change) in samples collected from control
legionellosis patients before ﬂuoroquinolone administration, as well as
in the D3 sample (0.037% of 5258 reads) frompatient #1. These later re-
sults suggested that, in some legionellosis patients, the gyrA83mutants
of L. pneumophila were present in the lower respiratory airways before
administration of any antibiotic therapy.
For patients #2, a reference gyrA QRDR was detected in the D0
sample, but a C248T mutation resulting in the T83I GyrA change was
found in the analyzed D4 sample, suggesting in vivo selection of
ﬂuoroquinolone-resistant mutants. Using NGS, we conﬁrmed the
presence of the C248T gyrA83 mutation in respiratory samples. It oc-
curred at a frequency of 2.9% of 7205 reads at D0, increasing to 94% of
16,794 reads in the D4 sample after 4 days of treatment with
levoﬂoxacin and azithromycin (Table 1). The high proportion of
gyrA83 mutants in sample D4 of patients #2 conﬁrmed the melting
curve proﬁles of the qPCRgyrALp assay. Patient #2 recovered from
legionellosis under levoﬂoxacin and azithromycin therapy, after
31 days at ICU and a total of 79 days at hospital (Fig. 2).
For patients # 4, a reference gyrA QRDRwas detected in the D0 sam-
ple, but a C248T mutation resulting in the T83I GyrA change was found
in both D3 and D5 samples, suggesting in vivo selection of
ﬂuoroquinolone-resistant mutants. Using NGS, the C248T gyrA83muta-
tion was detected in 1.05% of 8063 reads at D0, increasing to 75% of
15,824 reads and 85% of 16,050 reads at D3 and D5, respectively,
while the patient was receiving ciproﬂoxacin and erythromycin in theeaks obtained with the qPCRgyrALp assay are shown for the L. pneumophila Paris strain
he L. pneumophila Lorraine strain (Pendleton et al., 2013), the L. pneumophila Philadelphia
umophilaParismutant strains LPPI1 and LPPI4 harboring one (Maurin et al., 2001), and two
re expressed as ﬂuorescence levels derived through time.Melting peaks of 59.34±0.41 °C
ely.
Table 1
Results of the qPCRgyrALp assay with melting temperature (Tm), and presence or absence of the gyrA83/T83I QRDR change determined by PCR ampliﬁcation and sequencing (PCR-Seq),
and Next-Generation Sequencing (NGS, with the percentage of gyrA83mutant alleles among sequencing reads) for the 139 respiratory samples collected from the 82 patients.
Patients (n = 82) Respiratory samples (n = 139) Day of samplinga qPCRgyrALp T83I GyrA change
FQ No FQ NAb Total (Tm) PCR-Seq NGS
n = 20 8 2 10 20 Negative ND
n = 58 3 0 1 4 Negative ND
54 10c 40 104 Positive (~60 °C) ND Yes (b0.5%)
#1 1 1 D1 Positive (~60 °C) NPA No
1 1 D3 Positive (~56 °C) NPA Yes (b0.5%)
1 1 D7 Negative ND ND
#2 1 1 D0 Positive (~60 °C) No Yes (2.9%)
1 1 D4 Positive (~56 °C) Yes Yes (94%)
1 1 D4 Positive (~56 °C) ND ND
#3 1 1 D0 Positive (~56 °C) No No
#4 1 1 D0 Positive (~60 °C) No Yes (1.05%)
1 1 D2 Positive (~60 °C) ND ND
1 1 D3 Positive (~56 °C) Yes Yes (75%)
1 1 D5 Positive (~56 °C) Yes Yes (85%)
Total 75 13 51 139
Data are given according to the patient's ﬂuoroquinolone (FQ) treatment status at the time of respiratory sample collection. ND: not determined. NPA: no PCR ampliﬁcation.
a Days of sampling are given according to the day of legionellosis diagnosis (D0).
b FQ treatment information not available.
c Including three D0 samples tested by NGS for the three control patients.
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tants in samples D3 and D5 conﬁrmed the melting curve proﬁles of
the qPCRgyrALp assay. For this patient, we investigated the dynamics
of both the DNA load and gyrA83 allele by combining the qPCRmip
and NGS approaches. While the global DNA load remained stable in re-
spiratory samples from D0 to D5, the gyrA83mutated alleles progres-
sively replaced the wild-type alleles, suggesting an increase in the
ﬂuoroquinolone-resistant population of L. pneumophila, parallel to the
reduction of the susceptible population (Fig. 3). Patient #4 was ﬁrst ad-
mitted to a hematologic ward for severe pneumonia and aplasia, and
transferred after 11 days at ICU because of health worsening despite a
three-day course of ciproﬂoxacin, ceftazidime and teicoplanin (Fig. 3).
He was cured under ciproﬂoxacin and erythromycin therapy, with a
32-day hospital stay including 7 days at ICU.
We investigatedwhether a correlationmay exist between a positive
qPCRgyrALp assay, the presence of gyrA83 mutations in respiratory
samples and severe legionellosis evolution (Table 2). A trend was
noted, albeit not signiﬁcant, for more frequent admission to the ICU
for patients with a positive qPCRgyrALp assay. Also, patients with a pos-
itive qPCRgyrALp assay were more likely to receive a combination of a
macrolide and a ﬂuoroquinolone during their hospital stay. NoFig. 2.Clinical history and gyrA83mutational dynamics for patients #2. The results of qPCRmip, q
over his hospitalization stay. The number of days for relevant steps during hospitalization is giv
determined by a positive urinary antigen test (UAT+). qPCR-mip+ indicates a positive qPCRm
ampliﬁcation of the gyrAQRDR), “wt” and “mut” (a positive PCR assaywith a reference andmut
gyrA83mutation, determined by next-generation sequencing, is shown (NGS-mut). Small ar
azithromycin; Ery: erythromycin; Amc: amoxicillin-clavulanate; Ca: ceftazidime; Tc: teicoplansigniﬁcant difference was observed between the qPCRgyrALp results
and the mean global hospital stay or death. A correlation between the
presence of gyrA83mutations in respiratory samples and a worse prog-
nosis was impossible to establish because only 2 patients of 82
displayed such criterion.
4. Discussion
It has commonly been assumed that L. pneumophila could not devel-
op ﬂuoroquinolone resistance (Jespersen et al., 2010; Yu et al., 2009;
Pedro-Botet and Yu, 2009; Burdet et al., 2014). Very recently however,
a ﬂuoroquinolone-resistant strain of L. pneumophila was isolated in a
legionellosis patient treated with ciproﬂoxacin (Bruin et al., 2014).
This unique and preliminary observation raises the question of the dy-
namics and origin of ﬂuoroquinolone resistance in L. pneumophila. It
has been speculated that the environmental release of antibiotics may
promote the emergence of antibiotic-resistant bacterial lineages
(Davies and Davies, 2010), but this has never been demonstrated for
Legionella species. Here, using a combination of molecular and genomic
approaches, we investigated the infection dynamics of two legionellosis
patients in a cohort of 82 during their hospitalization.We demonstratedPCRgyrALp andNGS assays are shown, togetherwith the antibiotic therapy for patients #2
en inside circles according to D0which corresponds to the day of legionellosis diagnosis as
ip assay in respiratory samples. Results of the qPCRgyrALp assay are indicated as “neg” (no
ant-typemelting peak, respectively). The proportion of the reads corresponding to the T83I
rows indicate the periods of antibiotic therapy. Lev: levoﬂoxacin; Cp: ciproﬂoxacin; Azi:
in.
Fig. 3.Clinical history, and dynamics of L. pneumophilaDNA load and gyrA83mutations in respiratory samples from patient #4. (a) The results of qPCRmip, qPCRgyrALp andNGS assays are
shown, together with the antibiotic therapy for patients #4 over his hospitalization stay (see legend of Fig. 2). (b) Dynamics of L. pneumophila DNA load, expressed as log GU/mL clinical
sample, in respiratory samples of patient # 4 over time after admission in ICU. The total, reference, and mutant gyrA QRDR DNA loads are shown by circles, triangles and squares, respec-
tively. Data were extracted from the qPCRmip assay and NGS experiments. (c) Relative proportion of the reference (triangles) and mutant (squares) gyrAQRDR allele in respiratory sam-
ples of patient # 4 over time after admission in ICU. Data were extracted from the NGS experiments.
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of L. pneumophila that evolved in vivo toward a high load of
ﬂuoroquinolone-resistant gyrA83mutants after antibiotic therapy.
We designed a qPCRgyrALp assay that allowed us to detect a signal
for the gyrA QRDR in 114 samples from 62 of the 82 patients, including
63 samples collected in patients under ﬂuoroquinolone treatment. We
found gyrA83 mutations in two patients (3.1%, patients #2 and #4).
We did not seek mutations in either other gyrA regions or other
topoisomerase-encoding genes owing to the small amount of biological
material, but such mutations may occur in vitro (Almahmoud et al.,Table 2
Analyses of potential correlations between parameters (qPCRgyrALp assay, qPCRmip assay, antib
qPCR gyrALp Patients (n = 82) qPCRmip Legionellosis treatmen
Positive Negative FQ only (n) FQ +
Positive 62 58 4 22 20
Negative 20 3 17 11 0
p b 0.001† 0.004†
All numbers correspond to patients.
a FQ: ﬂuoroquinolone; MC: macrolide.
† Fisher exact tests were performed.
†† Chi2 tests with Yates correction were performed.
††† t tests were performed.2009). Thus, we have likely underestimated the incidence of in vivo se-
lection of ﬂuoroquinolone resistance in L. pneumophila. We investigated
the presence of a correlation between a positive qPCRgyrALp assay and
higher legionellosis severity in the 82patients of the cohort. Therewas a
trend for the 62 patients with a positive qPCRgyrALp assay to be more
frequently admitted to the ICU, and these patients more frequently re-
ceived a combination of a macrolide and a ﬂuoroquinolone then those
with a negative qPCRgyrALp assay. These ﬁndings may reﬂect higher
L. pneumophila bacteria load in their respiratory samples, whichwe pre-
viously correlatedwith higher severity of the disease using the qPCRmipiotic treatment, duration of stay at hospital and ICU, death) for all 82patients of the cohort.
ta Hospital stay (mean days +/−SD) ICU admission (n) Death (n)
MC (n)
18.1 +/− 16.1 21 5
14.3 +/− 11.7 2 0
0.23††† 0.07†† 0.32†
1184 L. Shadoud et al. / EBioMedicine 2 (2015) 1179–1185assay (Maurin et al., 2010). Indeed, there was a signiﬁcant correlation
between results of the qPCRgyrALP and qPCRmip assays.
A gyrA83mutation leading to theGyrA T83I substitution is likely to be
clinically signiﬁcant for two main reasons: ﬁrst we previously demon-
strated that it produced at least a four-fold increase of ciproﬂoxacin
MIC in L. pneumophila Paris (Almahmoud et al., 2009), and second it is
known to be associated with high-level ﬂuoroquinolone resistance in
other Gram-negative bacteria (Komp Lindgren et al., 2003; Jacoby,
2005). We detected a rapid increase of gyrA83mutant alleles under ﬂu-
oroquinolone treatment to 94% at D4 for patient #2 and 75% and 85% at
D3 and D5, respectively, for patient #4. For this latter patient, a
ﬂuoroquinolone-susceptible strain of L. pneumophila sg1 was isolated
from respiratory samples at D0. During the stay of patient #4 at ICU,
we observed a major in vivo shift in the structure of the L. pneumophila
population with the replacement of ﬂuoroquinolone-susceptible by re-
sistant cells, conﬁrming that ﬂuoroquinolone therapy selected for
in vivo ﬂuoroquinolone resistance during hospitalization. The two pa-
tients #2 and #4 suffered from a severe and prolonged course disease,
but recovered under combined ﬂuoroquinolone and macrolide treat-
ment. Additional caseswill be needed to establish a statistical correlation
between the disease severity and the in vivo selection of gyrAQRDRmu-
tant strains of L. pneumophila. We found by NGS a very low percentage
(b0.5%) of mutated alleles in respiratory samples from control patients
and in sample D3 from patient #1, and a slightly higher percentage
(1.05% and 2.9%, respectively) in sample D0 from patients #2 and #4.
These sequences may correspond to false positives introduced during
the PCR ampliﬁcation step of the NGS process itself. Alternatively, they
may reﬂect the spontaneous occurrence of ﬂuoroquinolone-resistance
mutations in L. pneumophila, as previously described in other Gram-
negative bacteria including E. coli (Komp Lindgren et al., 2003). There-
fore, legionellosis patients might have been infected with a complex
L. pneumophila population containing low abundance of gyrA83mutants,
with subsequent selection of this population in patients #2 and#4 under
ﬂuoroquinolone therapy. An alternative hypothesis could be the in vivo
emergence of thesemutants. The rapid increase in the proportion ofmu-
tated gyrA83 alleles over a few days is more compatible with the former
hypothesis. In both cases however, the selective sweeps resulting in the
increased abundance of the gyrA83mutants occurred in vivo during ﬂu-
oroquinolone treatment.We emphasize that patient #4 already received
a three-day course of ciproﬂoxacin at D0.
We have shown that in vivo selection of gyrAmutations responsible
for ﬂuoroquinolone-resistance in L. pneumophila occurs in legionellosis
patients during ﬂuoroquinolone treatment. A likely hypothesis is that
patients were infected with L. pneumophila populations containing low
doses of gyrA83mutants. If so, it is puzzling that no ﬂuoroquinolone re-
sistance has been so far characterized in environmental strains of
L. pneumophila, and only a single ﬂuoroquinolone-resistant strain of
this species has been isolated before in a clinical situation (Bruin et al.,
2014). It should be emphasized that mutant strains of L. pneumophila
have poor ability to propagate outside infected hosts because of the
lack of human-to-human transmission and little opportunities to go
back to their natural environmental reservoir. However, isolation of
L. pneumophila from respiratory samples of legionellosis patients re-
mains challenging, and almost impossible in patients under antibiotic
therapy. We recommend the development and use of molecular tools
to test the presence of resistance mutations in patients infected by
L. pneumophila, especially in the case of poor response to antibiotic treat-
ment. Our strategy should be optimized to allowmore speciﬁc detection
of gyrA83 and gyrA87 mutations, and other previously characterized
ﬂuoroquinolone-resistance mutations (Almahmoud et al., 2009; Jonas
et al., 2003; Nielsen et al., 2000). This would allow to precisely deﬁne
the prevalence of ﬂuoroquinolone-resistant mutants in legionellosis pa-
tients and their clinical consequences. The molecular tools could also
serve to assess the emergence and spread of gyrA83mutants in environ-
mental L. pneumophila strains. The possibility of in vivo selection for
ﬂuoroquinolone-resistance mutations in L. pneumophila fully justiﬁesthe current practice of administration of combined antibiotic therapy
in severe legionellosis cases (Roig and Rello, 2003). Our study showing
in vivo L. pneumophila adaptation to antibiotic pressure paves the way
for more intensive investigations of other intracellular bacterial species.
This hidden resistance should indeed be intensively explored because
it may contribute to the increasing public health threat of the gradual
loss of effectiveness of antibiotic treatments.
In conclusion, although ﬂuoroquinolones and macrolides are highly
active against Legionella species, death rates of 10–15% are commonly re-
ported in legionellosis patients. No correlation can be found in the liter-
ature between treatment failures or relapses and development of
antibiotic resistance in Legionella spp. However, ﬂuoroquinolone-
resistant strains of L. pneumophila have been selected in vitro, and a
ﬂuoroquinolone-resistant isolate was recently obtained from a
legionellosis patient. By using state-of-the-art molecular and genomic
approaches, we identiﬁed, at high frequency, ﬂuoroquinolone resistance
mutations in lower respiratory samples from two additional legionellosis
patients from a cohort of 82. The detected gyrA83mutation is associated
with a signiﬁcant increase in ﬂuoroquinolones MICs in L. pneumophila.
We demonstrated that selection for ﬂuoroquinolone resistance occurred
in vivo during ﬂuoroquinolone therapy. These two patients required ICU
admission and prolonged hospitalization, but recovered under com-
bined ﬂuoroquinolone and macrolide treatment. Although the exact
clinical impact of our ﬁndings could not be statistically evaluated be-
cause only two out of 82 legionellosis patients were involved, the possi-
bility of in vivo selection of ﬂuoroquinolone resistance in L. pneumophila
should now be considered both for prognostic evaluation and treatment
optimization at least in patients with severe legionellosis.
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